Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.

A StallmachC LangbeinR AtreyaKaren SchmidtA DignassK EndeJ HampeF HartmannM F NeurathJ MaulJ C PreissR SchmelzB SiegmundH SchulzeN TeichU von ArnimD C BaumgartC Schmidt

Published in: Alimentary pharmacology & therapeutics (2016)

Among patients who started vedolizumab for active inflammatory bowel disease, clinical remission rates are 21-25% after 54 weeks.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
rheumatoid arthritis
cross sectional
disease activity
gestational age